AUTHOR=Fan Qian-Ya , Zhang Xiao-Dong , Hu Ze-Di , Huang Shi-Shi , Zhu Shi-Guo , Chen Cai-Ping , Zhang Xiong , Wang Jian-Yong 

TITLE=Case report: Blepharospasm in peak-dose dyskinesia may benefit from amantadine in Parkinson's disease

JOURNAL=Frontiers in Neurology

VOLUME=Volume 13 - 2022

YEAR=2022

URL=https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2022.961758

DOI=10.3389/fneur.2022.961758

ISSN=1664-2295

ABSTRACT=Introduction: Blepharospasm is uncommon in Parkinson's disease, especially in peak-dose dyskinesia period.
Case presentation: We herein presented a case of PD patient, who developed blepharospasm in the peak-dose dyskinesia period. The symptom was improved by taking amantadine.
Conclusion: The current report expands the phenomenology of peak-dose dykinesia in PD to include dystonic blepharospasm. This complication of levodopa therapy may respond to amantadine despite the dystonic appearance of the movements.